Back to results
US 9,333,280 B2Granted
Stabilized enzyme compositions
AssigneeTeleflex Medical Incorporated
InventorNisha Gupta
Life of this patent
Estimating the term…
Abstract
A medical device includes a base material having an immobilized enzyme and dextran sulfate. The dextran sulfate has a molecular weight that is less than 40 kilo dalton (kDa). The medical device is formed from at least a base material. An enzyme is immobilized on the base material. The enzyme is stabilized with a dextran sulfate having a molecular weight of less than 40 (kDa).
Claims18
A medical device, comprising:
- a base material;
- and
- an immobilized enzyme covalently bound to the base material in the presence of dextran sulfate,
- wherein the medical device is configured to be implanted in the vascular system of a patient, and
- wherein the dextran sulfate has a molecular weight of about 8 kilodaltons (kDa) to stabilize the immobilized enzyme when in contact with blood of the patient.
2 more elements
A medical device, comprising:
- a polyurethane base material configured to be implanted in the vascular system of a patient;
- an amount of a blood clot digestive enzyme sufficient to reduce the formation of device related blood clots and an amount of an extracellular matrix digestive enzyme sufficient to reduce neo-initimal hyperplasia, the enzymes being immobilized on the medical device by covalently binding the enzymes to the polyurethane base material;
- a low molecular weight dextran sulfate configured to stabilize the enzymes when in contact with blood of the patient, the low molecular weight dextran sulfate having a molecular weight of about 8 kilodaltons;
- and
- an antimicrobial agent disposed in the polyurethane base material in an amount sufficient to reduce microbial growth.
2 more elements
A medical device comprising:
- a polyurethane base material configured to be implanted in the vascular system of a patient;
- an amount of an enzyme sufficient to reduce the formation of blood clots in a patient or sufficient to reduce neo-initimal hyperplasia, the enzyme being covalently immobilized in the base material;
- a low molecular weight dextran sulfate configured to stabilize the enzyme when in contact with blood of the patient, the low molecular weight dextran sulfate having a molecular weight of about 8 kilodaltons;
- and
- a chlorhexidine base or a pharmaceutically acceptable salt thereof disposed in the polyurethane base material in an amount sufficient to reduce microbial growth.
2 more elements
A medical device, comprising:
- a base material;
- an immobilized enzyme covalently bound to the base material in the presence of dextran sulfate;
- and
- a cationic selective antimicrobial impregnating the base material,
- wherein the medical device is configured to be implanted in the vascular system of a patient, and
- wherein the dextran sulfate has a molecular weight of about 8 kilodaltons (kDa) to stabilize the immobilized enzyme when in contact with blood of the patient.
3 more elements
Dependencies are inferred from the claim text.